Fermenta Biotech Ltd · NSE:FERMENTA
Fermenta Biotech — Q1 FY2025 Earnings Presentation
17 slides from Fermenta Biotech's earnings presentation, Aug 23, 2024
Slide 1: Intimation of Earnings Presentation to BSE
Ref: F.No.:908 August 23, 2024 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Earnings Presentation for Quarter 1 of Financial Year (‘FY’) 2024-25 [Q1-FY25] Ref: Scrip Code: 506414 Further to our intimation dated August
Slide 2: Earnings Presentation | Q1-FY25
Earnings Presentation | Q1-FY25
Slide 3: Snapshot
Snapshot Top 3 Only manufacturer of Amongst top 3 manufacturers Global Presence in Vitamin D3 in India of Vitamin D3 globally 60+ countries Proprietary technology to 55 Years of Vitamin D3 Both manufacturing facilities certified manufacture Vitamin D3 manufacturing experience by global regulatory bo
Slide 4: Company Overview
Company Overview • Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is engaged in development and manufacturing of pharmaceuticals, biotechnology and Consolidated Revenue (INR Mn) & EBITDA Margins (%) environmental solutions used across various industries. 3,
Slide 5: Q1-FY25 Financial Overview
Q1-FY25 FINANCIAL OVERVIEW
Slide 6: Q1-FY25 Financial Highlights
Q1-FY25 Financial Highlights Q1-FY25 Standalone Performance Q1-FY25 Consolidated Performance INR 727 Mn INR 19 Mn 2.61% INR 781 Mn INR 8 Mn 1.02% Operational Income Operational EBITDA Operational EBITDA Margin Operational Income Operational EBITDA Operational EBITDA Margin INR (48) Mn (6.60)% INR (1
Slide 7: Q1-FY25 Operational Highlights
Q1-FY25 Operational Highlights • Volumes of Vitamin D3 for Human Nutrition in Q1FY25 was higher by 48% compared to Q1FY24 and 33% lower as compared to Q4FY24, while the average prices of Vitamin D3 for Human Nutrition were higher by 2% in Q1FY25 as compared to Q1FY24 and 10% higher over Q4FY24. In Q
Slide 8: Vitamin D3 Animal Feed Price Trend
Vitamin D3 500 Animal Feed Price Trend 85 80 75 60 Price (Euro/kg) 33 32 30 25 22 20 20 16 13 12 12 9 10 8 8 7 6 6 6 7 7 7 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Q2 2024 Calendar Year Source: feedinfo.com Min of Low Max of High Fermenta Biotech Limited 7
Slide 9: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance PARTICULARS (INR Mn) Q1-FY25 Q1-FY24 Y-o-Y Q4-FY24 Q-o-Q Operational Revenue 727 768 (5.3)% 897 (19.0)% Total Expenses 708 635 11.4% 808 (12.4)% Operational EBITDA 19 132 (85.6)% 89 (78.7)% Operational EBITDA Margins (%) 2.61% 17.19% NA 9.92% (731) Bps Othe
Slide 10: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance PARTICULARS (INR Mn) Q1-FY25 Q1-FY24 Y-o-Y Q4-FY24 Q-o-Q Operational Revenue 781 824 (5.3)% 973 (19.7)% Total Expenses 773 715 8.1% 919 (15.9)% Operational EBITDA 8 109 (92.7)% 54 (85.2)% Operational EBITDA Margins (%) 1.02% 13.26% NA 5.55% (453) Bps Othe
Slide 11: Historical Standalone Income Statement
Historical Standalone Income Statement PARTICULARS (INR Mn) Q1-FY25 FY24 FY23 FY22 Operational Revenue 727 3,071 3,289 3,880 Total Expenses 708 2,701 2,905 3,120 Operational EBITDA 19 370 384 760 Operational EBITDA Margins (%) 2.61% 12.05% 11.68% 19.59% Other Income 26 82 85 75 Depreciation 59 237 2
Slide 12: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) Q1-FY25 FY24 FY23 FY22 Operational Revenue 781 3,357 3,499 3,985 Total Expenses 773 3,082 3,323 3,371 Operational EBITDA 8 275 176 614 Operational EBITDA Margins (%) 1.02% 8.19% 5.12% 15.41% Other Income 28 118 86 81 Depreciation 61 247 2
Slide 13: Historical Standalone Balance Sheet
Historical Standalone Balance Sheet PARTICULARS (INR Mn) FY24 FY23 FY22 PARTICULARS (INR Mn) FY24 FY23 FY22 Equity 3,142 3,360 3,959 Assets Non-current Assets 3,264 4,105 3,974 a) Equity share capital 144 144 144 a) Property, plant and equipment 2,364 2,048 1,935 b) Other equity 2,998 3,216 3,815 b)
Slide 14: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet PARTICULARS (INR Mn) FY24 FY23 FY22 PARTICULARS (INR Mn) FY24 FY23 FY22 Equity 2,851 3,126 3,714 Assets a) Equity share capital 144 144 144 Non-current Assets 3,061 3,835 3,928 a) Property, plant and equipment 2,364 2,048 1,935 b) Other equity 2,744 3,009 3,577
Slide 15: Historical Consolidated Financial Performance
Historical Consolidated Financial Performance Operational Revenue (INR Mn) Operational EBITDA (INR Mn) & Margins (%) PAT (INR Mn) & Margins (%) 154 3,985 15.41% 614 3,499 3,357 3.86% FY22 FY23 FY24 Q1-FY25 8.19% -59 275 -7.15% 5.12% -7.55% -240 176 781 1.02% -15.18% 8 -531 FY22 FY23 FY24 Q1-FY25 FY2
Slide 16: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 17: Thank You
Thank You